Saturday 17 October 2026
Export HYPD’s income statement to Excel — free account
Hyperion DeFi, Inc.
HYPD Healthcare Biotechnology
Hyperion DeFi, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $813,500.00, up 1,319.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,333.3%, EPS grew 140.4%, free cash flow grew 86.8% and total debt rose 12.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.84
0.31
−9.84%
Follow HYPD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
166.46 | 21.15 | 34.61 | 31.77 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.46) | (4.39) | (8.72) | (15.36) | |
P/B ratio |
0.82 | 0.43 | 0.63 | 0.44 | |
Price to Tangible BV |
1.62 | 0.87 | 0.86 | 0.58 | |
EV/Sales |
191.57 | 33.94 | 42.99 | 30.92 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 8.85 | |
EV/Operating CF |
(3.95) | (1.93) | (3.13) | (3.10) | |
EV/FCF |
(0.81) | (0.36) | (0.57) | (0.56) | |
Quick Ratio |
2.04 | 2.34 | 1.65 | 1.75 | |
Current Ratio |
2.25 | 2.68 | 1.97 | 2.34 | |
Net Debt/EBITDA |
(0.13) | (0.04) | (0.05) | (0.04) | |
Debt/Assets |
9.25% | 15.06% | 9.94% | 7.46% | |
Debt/Equity |
0.11 | 0.19 | 0.12 | 0.08 | |
Asset Turnover |
0.01 | 0.03 | 0.03 | 0.02 | |
Operating CF/Net income |
(0.48) | 0.10 | (1.30) | (0.20) | |
Capex/Depreciation |
(1,182.20) | 0.00 | 0.00 | (120.79) | |
Interest Coverage |
19.85 | (176.89) | 38.65 | 132.62 | |
Research and Development Expense of Revenue |
123.60% | 38.09% | 117.40% | 16.35% | |
Selling, General and Administrative Expense of Revenue |
857.55% | 913.04% | 1,839.38% | 1,095.50% | |
Intangible Assets out of Total Assets |
0.42 | 0.40 | 0.23 | 0.23 | |
Share Based Compensation of Revenue |
(445.29%) | 355.84% | 738.64% | 456.33% | |
Graham Net Nets |
(0.05) | (0.19) | (0.08) | 0.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(200.11%) | (325.56%) | (281.16%) | (197.13%) | |
Free Cash Flow Yield |
(142.80%) | (451.70%) | (218.98%) | (173.40%) | |
Revenue per Share |
0.05 | 0.10 | 0.02 | 0.03 | |
Operating CF per Share |
(0.47) | (0.81) | (0.40) | (0.20) | |
Capex per Share |
(10.89) | 0.00 | 0.00 | 0.17 | |
Free Cash Flow per Share |
(11.35) | (0.81) | (0.40) | (0.03) | |
Cash per Share |
1.36 | 1.26 | 0.70 | 0.68 | |
Shareholders Equity per Share |
11.74 | 8.21 | 5.51 | 7.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.74 | 8.21 | 5.51 | 7.19 | |
Free Cash Flow |
(68.43) | (4.06) | (4.20) | (0.46) | |
Working Capital |
5.05 | 4.54 | 4.33 | 7.40 | |
Capital Expenditures |
(65.61) | — | — | 2.44 | |
Net Current Asset Value |
(2.95) | (3.46) | (2.77) | 1.70 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 9.84 | |
Capex to Sales |
216.90 | 0.00 | 0.00 | (6.82) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 10.11 | |
| Other line items | |||||
Average Payables |
1.36 | 1.14 | 0.81 | 0.52 | |
Average Assets |
52.79 | 27.72 | 38.03 | 84.40 | |
Average Common Equity |
37.24 | 13.98 | 24.39 | 69.65 |
Columns are period end dates